DrugPatentWatch Database Preview
Belatacept - Biologic Drug Details
» See Plans and Pricing
Summary for belatacept
| Tradenames: | 1 |
| Patents: | 23 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for belatacept |
Recent Clinical Trials for belatacept
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Veloxis Pharmaceuticals | Early Phase 1 |
| Vanderbilt University Medical Center | Early Phase 1 |
| Marlena V. Habal | Phase 2 |
Pharmacology for belatacept
| Mechanism of Action | CD80-directed Antibody Interactions CD86-directed Antibody Interactions |
| Physiological Effect | T Lymphocyte Costimulation Activity Blockade |
Patent Text Search: US Patents for belatacept
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | NULOJIX | belatacept | INJECTABLE; INJECTION | 125288 | 001 | 2011-06-15 | Start Trial | Perle Bioscience, Inc. (Atlanta, GA) | 2032-09-27 | RX | Orphan | search |
| Bristol Myers Squibb | NULOJIX | belatacept | INJECTABLE; INJECTION | 125288 | 001 | 2011-06-15 | Start Trial | Bristol-Myers Squibb Company (Princeton, NJ) Domantis Limited (Brentford, Middlesex, GB) | 2031-10-13 | RX | Orphan | search |
| Bristol Myers Squibb | NULOJIX | belatacept | INJECTABLE; INJECTION | 125288 | 001 | 2011-06-15 | Start Trial | Momenta Pharmaceuticals, Inc. (Cambridge, MA) | 2039-02-26 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for belatacept
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2012322093 | Start Trial |
| Poland | 2766395 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2019135829 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for belatacept
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 11C/041 | Belgium | Start Trial | PRODUCT NAME: BELATACEPT; AUTHORISATION NUMBER AND DATE: EU/1/11/694/001 20110623 |
| 1248802/01 | Switzerland | Start Trial | PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: SWISSMEDIC 61521 15.12.2011 |
| 2011 015 | Romania | Start Trial | PRODUCT NAME: BELATACEPT PROTEINA SOLUBILA DE FUZIUNE REPREZENTATA DEDOMENIUL EXTRACELULAR MODIFICAT AL CTLA-4 FUZIONAT CU REGIUNILE CH2-CH3 ALE IMUNOGLOBULINEI G1 UMANE; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/694/001, RO EU/1/11/694/002; DATE OF NATIONAL AUTHORISATION: 20110617; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/694/001, EU/1/11/694/002; DATE OF FIRST AUTHORISATION IN EEA: 20110617 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
